The Trump administration's effort to impose new requirements on Novavax's COVID-19 vaccine -- the nation's only traditional ...

There’s new uncertainty about updated COVID-19 shots this fall after the Trump administration’s handling of a shot from ...

Novavax Inc. closed 73.09% below its 52-week high of $23.86, which the company achieved on June 6th.

Novavax’s COVID-19 vaccine could soon receive full approval from the United States Food and Drug Administration.

Comments over the weekend by FDA chief Martin Makary suggest the agency views Novavax’s updated COVID shot as a “new product” ...

The President Donald Trump administration's request for Novavax Inc. to conduct new clinical trials for its COVID-19 vaccine ...

Novavax said Monday morning that the Food and Drug Administration was asking the company to run a new trial of its Covid-19 ...

CHICAGO, April 24 (Reuters) - Thousands of Americans campaigning for the Novavax (NVAX.O), opens new tab COVID-19 booster got some good news this week: the FDA signaled it might still win approval ...

The US Food and Drug Administration has discussed with vaccine-maker Novavax the need for an additional trial of its Covid-19 vaccine as a post-approval commitment, a source familiar with the ...

Federal regulators are asking Novavax NVAX0.52%increase; green up pointing triangle to complete an additional randomized clinical trial on its Covid-19 vaccine after previously delaying approval ...

Novavax recently announced preliminary results from its SHIELD-Utah study, showcasing the Novavax COVID-19 vaccine's effectiveness and reduced side effects compared to a competitor's vaccine.

Shares of Novavax (NASDAQ:NVAX) rose on Wednesday after the company revealed a U.S. FDA request for additional clinical data on its COVID-19 vaccine post approval. After missing a key deadline to ...